No effects of antidepressants on negative symptoms in schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 686-690

  Hinkelmann, Kim ^a   Yassouridis, Alexander ^a   Kellner, Michael ^a   Jahn, Holger ^a   Wiedemann, Klaus ^a   Raedler, Thomas J ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE;

ABDOMINAL DISCOMFORT; ADD ON THERAPY; ADULT; AGITATION; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DSM-IV; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AFFECT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CITALOPRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883793795     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182971e68     Document Type: Article

References (25)

1. Konstantakopoulos G, Ploumpidis D, Oulis P, et al. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr Res. 2011;133:193-198
2. Makinen J, Miettunen J, Isohanni M, et al. Negative symptoms in schizophrenia: A review. Nord J Psychiatry. 2008;62:334-341
3. Rummel-Kluge C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD005581
4. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: Future prospects. Schizophr Bull. 2006;32: 234-237
5. Singh SP, Singh V, Kar N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: Meta-Analysis. Br J Psychiatry. 2010;197:174-179
6. Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: A meta-Analysis. J Clin Psychiatry. 2007;68: 604-610
7. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial. Psychiatry Res. 2010;179:19-23
8. Siris SG. Depression in schizophrenia: Perspective in the era of atypical antipsychotic agents. Am J Psychiatry. 2000;157: 1379-1389
9. Levinson DF, Umapathy C, Musthaq M. Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry. 1999;156:1138-1148
10. Whitehead C, Moss S, Cardno A, et al. Antidepressants for the treatment of depression in people with schizophrenia: A systematic review. Psychol Med. 2003;33:589-599
11. Furtado VA, Srihari V. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev. 2008:CD005377
12. Marcus MM, Jardemark K, Malmerfelt A, et al. Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology. 2010;35:1952-1961
13. Raedler TJ, Jahn H, Arlt J, et al. Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry. 2004;19:366-369
14. Kay SR, Opler LA, Fizsbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1986
15. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62
16. Guy W. Assessment Manual for Psychopharmacology. Rockville, MD: National Institutes of Health; 1976
17. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19
18. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676
19. Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;438:7-14
20. Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: A preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001;16: 275-278
21. Poyurovsky M, Isaacs I, Fuchs C, et al. Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study. Am J Psychiatry. 2003;160:297-302
22. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for subsyndromal symptoms of depression in middle-Aged and older outpatients with schizophrenia and schizoaffective disorder: A randomized controlled trial. J Clin Psychiatry. 2009;70: 562-571
23. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-Treatments meta-Analysis. Lancet. 2009;373:746-758
24. Moller HJ. Clinical evaluation of negative symptoms in schizophrenia. Eur Psychiatry. 2007;22:380-386
25. Stauffer V, Case M, Kollack-Walker S, et al. Trajectories of response to treatment with atypical antipsychotic medication in patients with schizophrenia pooled from 6 double-blind, randomized clinical trials. Schizophr Res. 2011;130:11-19